News Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator Jun 02, 2023 Posted by Societal CDMO
News Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™ Jun 02, 2023 Posted by Societal CDMO
News Societal CDMO Signs Multiple Project Expansion Agreements With Existing Customers Jun 02, 2023 Posted by Societal CDMO
News Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352 Jun 02, 2023 Posted by Societal CDMO
News Societal CDMO Announces U.S. FDA Approval for Manufacturing of Commercial Tablet at Gainesville, Georgia Site Jun 02, 2023 Posted by Societal CDMO
News Freshfields Advises SERB Pharmaceuticals on its U.S. Partnership with SFJ Pharmaceuticals Jun 01, 2023 Posted by Freshfields
News Ongoing Initiatives at the USPTO and FDA and Their Potential Impact on the Life Sciences Industry in the United States Jun 01, 2023 Posted by Freshfields
News FTC v. Amgen/Horizon: FTC’s Pursuit of a Novel Theory Signals Greater Scrutiny on the Horizon for Pharmaceutical Mergers Jun 01, 2023 Posted by Freshfields